























Panel	1:	The	child	with	cancer	in	resource-limited	settings	In	LMIC	(we	define	LMIC	according	 to	World	Bank	 income	group	classification	 in	2016	–	appendix	page	28)	unacceptable	excess	in	treatment	failure	for	children	with	cancer	results	from	a	malfunction	of	every	step	in	the	care	cascade	from	diagnosis,	to	referral	to	treatment,	follow	up	and	palliative	 care.14	 Inadequate	healthcare	 infrastructure	and	service	delivery	networks,	 limited	access	 to	quality	medicines,	 lack	of	multidisciplinary	health	workforce,	
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low-quality	of	care	adverse	socio-economic	environment,	cultural	and	educational	barriers,	and	 lack	of	awareness	both	at	 the	societal	 level	as	well	as	within	the	medical	community	result	 in	 missed	 diagnosis,	 under-ascertainment,	 delayed	 and	 under	 diagnosis	 and	suboptimal	 care	 of	 childhood	 cancer	 in	 LMIC.15,16,17	 Other	 factors	 also	 contribute	 to	suboptimal	care	and	poor	outcomes,	including:		(i)	Refusal	 and	abandonment	of	 therapy:	 refusal	 and	abandonment	of	 therapy	 is	 a	major	cause	of	therapeutic	failure	in	countries	with	limited	resources,	where	children	and	families	incur	unaffordable	direct	and	indirect	costs	of	care18,19,	and	affect	up	to	50-60%	of	children	in	some	world	regions	–	often	exceeding	all	other	causes	of	treatment	failure.11	Most	children	abandon	 early,	 usually	 after	 induction	 remission	 in	 leukaemias	 or	 at	 the	 time	 of	 radical	surgeries	(e.g.	enucleation	of	the	eye	or	amputation)	in	solid	malignancies.20,21			(ii)	Malnutrition:	the	prevalence	of	malnutrition	in	children	with	cancer	in	LMIC,	which	is	associated	with	higher	toxicity	rates,	reaches	50%	to	70%	in	some	regions	of	the	world	and	is	a	major	cause	of	decreased	survival.	22,23				(iii)	Lack	of	supportive	care:	the	ability	to	provide	state	of	the	art	curative	treatments	for	children	with	cancer	in	LMIC	is	severely	limited	by	the	lack	of	supportive	care	programmes,	most	 notably	 nutrition,	 and	 infection	 control.	 Death	 from	 infection	 during	 neutropaenic	episodes	is	much	higher	in	countries	with	limited	resources.24,25,26					(iv)	Lack	of	blood	products	and	transfusion	support:	availability	of	safe	blood	products	 is	
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 Source:	Survival	estimates	provided	by	the	Concord	programme	*	Data	with	100%	coverage	of	the	national	population		Note:	Morphology	groups	included	in	Table	3	are	based	on	the	second	tier	of	the	International	Classification	of	Childhood	Cancer	3rd	edition	(ICCC-3).	Therefore,	age-standardised	survival	estimates	are	for	all	astrocytomas	combined	and	for	all	embryonal	tumours	combined.	ICCC-3	does	include	a	third,	more	granular	tier	for	embryonal	tumours,	but	not	for	astrocytomas.	We	chose,	however,	not	to	estimate	survival	separately	for	embryonal	tumour	subtypes	in	this	third	tier	(medullolastoma,	primitive	neuro-ectodermal	tumour,	medulloepithelioma,	and	atypical	teratoid/rhabdoid	tumour),	because	small	numbers	would	not	have	allowed	production	of	robust,	age-standardised	survival	estimates.			Age-standardised	 five-year	 net	 survival	 for	 children	 diagnosed	with	 acute	 lymphoblastic	
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(95%	UI)	Global	 13,659,000	(12,542,000-15,002,000)	 7,532,000	(7,025,000-8,118,000)	 6,128,000	(5,445,000-6,937,000)	LIC	 3,359,000	 1,518,000	 1,842,000	
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Number	 Percent	 Undiscounted	 Discounted	(3%)	
Global	
		
Access/Referral	 905117	(728835-1104708)	 8.2%	(6.7%-9.8%)	 52.22	(42.79-63.11)	 15.22	(12.61-18.21)	Abandon	 237461	(150591-367746)	 2.1%	(1.3%-3.3%)	 12.05	(7.76-18.72)	 3.39	(2.17-5.3)	Treatment	 2020167	(1715794-2360370)	 18.2%	(15.9%-20.6%)	 102.25	(87.3-119.24)	 28.21	(24.07-32.79)	Comprehensive	 6235086	(5547779-7053927)	 56.1%	(53.6%-58.4%)	 318.4	(284.21-359.65)	 87.93	(78.74-99.08)	
LIC	
Access/Referral	 97975	(61543-152146)	 3.0%	(1.9%-4.6%)	 6.51	(4.62-9.34)	 2.02	(1.48-2.79)	Abandon	 61915	(34689-100701)	 1.9%	(1.1%-3%)	 3.09	(1.77-5.07)	 0.86	(0.5-1.41)	
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		The	substantially	larger	effect	of	Comprehensive	Scale-up,	compared	with	scaling	up	each	intervention	separately	along	the	care	cascade,	was	consistent	for	countries	in	all	World	Bank	income	groups.	The	health	benefits	of	comprehensive	scale-up	of	interventions,	in	terms	of	reduction	in	the	number	of	childhood	cancer	deaths,	are	projected	to	be	greatest	in	lower-middle-income	countries,	followed	by	low-income	countries.	In	contrast,	the	greatest	improvement	in	5-year	survival	is	projected	for	low-income	countries	(figure	9	and	table	7).		The	model	also	projected	improvements	among	high-income	countries,	
Treatment	 558863	(442909-700484)	 17.2%	(14%-20.5%)	 27.61	(22-34.59)	 7.51	(5.99-9.37)	Comprehensive	 1951183	(1666625-2330863)	 60.0%	(56.9%-62.8%)	 98.15	(83.82-117.31)	 26.68	(22.89-31.79)	
LMIC	
Access/Referral	 533115	(385111-711422)	 8.8%	(6.4%-11.5%)	 30.18	(22.49-39.66)	 8.86	(6.69-11.53)	Abandon	 127837	(58023-237512)	 2.1%	(0.9%-4%)	 6.35	(2.92-11.81)	 1.81	(0.83-3.38)	Treatment	 1150757	(925912-1407416)	 18.9%	(15.6%-22.1%)	 57.67	(46.4-70.98)	 16.07	(13.07-19.68)	Comprehensive	 3504948	(2973584-4079867)	 57.5%	(54.8%-59.7%)	 177.25	(150.64-205.99)	 49.46	(42.28-57.15)	
UMIC	
		
Access/Referral	 257255	(193174-344189)	 16.8%	(13.9%-20.1%)	 14.56	(10.87-19.54)	 4.08	(3.06-5.47)	Abandon	 43457	(16547-85437)	 2.9%	(1.1%-5.7%)	 2.37	(0.89-4.76)	 0.65	(0.25-1.29)	Treatment	 294053	(217402-378494)	 19.2%	(14.3%-23.9%)	 16.04	(11.77-20.83)	 4.39	(3.25-5.65)	Comprehensive	 739317	(615884-879019)	 48.3%	(45.7%-50.7%)	 40.73	(33.62-48.76)	 11.18	(9.3-13.34)	
HIC	
		





















































facility	tiers,	and	intervention	packages	Addressing	 childhood	 cancer	 requires	 the	 development	 of	 a	 specific	 framework	 that	 is	integrated	within	national	health	systems,	but	is	sensitive	to	the	unique	circumstances	that	
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define	 cancer	 in	 children,	 where	 comprehensive	 multidisciplinary	 care	 along	 the	 entire	continuum	of	care	is	critical.			Context	adaptation	of	guidelines	for	diagnosis	and	treatment	provides	an	opportunity	 for	policymakers	to	align	the	guidelines	with	the	available	resources	and	country	priorities	and	to	 plan	 resource-appropriate	 cancer	 care	 programmes	 for	 children.155,156	 The	implementation	of	these	tailored	approaches	will	require	the	development	and	validation	of	levels	of	care	that	accurately	reflect	the	status	of	regions,	countries	and	paediatric	oncology	units	of	interest.5,157,158			The	Commission	explored	this	concept	 further,	 to	develop	a	model	of	 ‘country	roadmaps’	and	‘facility	tiers’	with	integrated	service	packages	for	the	development	and	implementation	of	 childhood	 cancer	 care.	 Other	 health	 areas,	 such	 as	maternal	 and	 neonatal	 health,	 and	trauma	medicine	have	successfully	developed	and	implemented	care	models	based	on	levels	of	 care,159,160	 to	 show	 the	 correlation	 of	 those	 models	 with	 quality	 indicators	 and	outcomes.161,162,163				To	 develop	 a	 model	 of	 ‘country	 roadmaps’	 and	 ‘facility	 tiers’	 with	 integrated	 service	packages,	the	Commission	used	a	modified	Delphi	Process	with	three	rounds	of	surveys	to	derive	consensus	on	the	care	that	could	be	provided	at	each	level	and	the	country	capabilities	needed	to	provide	such	care.	The	respondents	to	the	Delphi	study	included	commissioners	and	 multidisciplinary	 experts	 (including	 paediatric	 oncologists	 and	 nurse	 specialists)	representing	all	WHO	regions	and	World	Bank	income	groups.	In	addition,	to	contextualize	
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the	 scoping	 review	 and	 complement	 the	 Delphi,	 working	 groups	 inclusive	 of	multidisciplinary	providers	experienced	with	intervention	needs	in	LMICs	met	in	person	and	online	over	a	period	of	more	than	18	months	to	review	evidence	and	refine	key	concepts	for	facility	and	country	tiers,	and	childhood	cancer	packages. 		Considering	 varied	 capabilities	 in	 countries	 the	 Commission	 identified	 country	 tiers	 and	identified	steps	to	progressively	transition	to	higher	capabilities	while	strengthening	health	systems	in	the	process	(panel	7).			
Panel	7:	Developing	tiers	of	capability	for	childhood	cancers	and	strengthening	health	
systems	Not	all	countries	are	equally	equipped	to	address	 the	burden	of	childhood	cancer,	but	all	countries	must	 consider	how	 they	 can	 improve	 the	quality	 of	 care	 and	population-based	outcomes	 for	 children	 with	 cancer	 within	 their	 resource	 constraints.	 The	 Commission	considered	that	elements	of	a	health	system	to	guide	the	definition	of	country	tiers	in	global	pediatric	oncology.	Defining	country	capabilities	can	help	develop	models	for	health	system	strengthening	of	greater	 impact	 than	achievable	by	 focusing	exclusively	on	strengthening	individual	facilities;	better	understand	the	country’s	capacity	and	the	country's	readiness	to	address	 and	 improve	 population-based	 childhood	 cancer	 outcomes;	 better	 evaluate	 and	benchmark	 population-based	 childhood	 cancer	 outcomes;	 and	 understand	 the	 country’s	readiness	 to	 have	more	 of	 its	 facilities	 ascend	 through	 facility	 tiers.	 Attentiveness	 to	 the	country	capabilities	can	improve	a	facility’s	understanding	of	its	role	in	the	health	system	and	help	 foster	 communication,	 integration,	 and	 common	purpose	between	 facilities	 and	
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with	 policy	makers	 and	 government	 agencies,	 and	 prioritize	areas	 in	 which	 a	 facility	 or	network	of	facilities	and	its	personnel	should	participate	in	advocacy.		The	 ‘steps’	 illustrate	 how	 progressive	 acquisition	 of	 these	 capabilities	 and	 stepwise	implementation	of	policy	enablers,	such	as	effective	stewardship	and	governance,	adequate	financing,	delivery	of	services	with	evidence-based	interventions	and	essential	medicines,	equitable	 access	 to	 care	 and	health	 information	 systems	with	 suitable	vital	 statistics	 and	cancer	 registries	 that	 include	 childhood	 cancer,	 can	 accelerate	 progress	 by	 easing	 the	facilities’	delivery	of	childhood	cancer	care	and	monitoring	and	evaluation	of	progress.	The	proposed	 country	 tiers	model	 needs	 to	 be	 interpreted	 as	 a	 roadmap	 towards	 a	 goal;	 the	framework	should	serve	as	a	consensus-derived	step-by-step	guide	of	health	system	policy	enablers	needed	for	optimal	delivery	of	childhood	cancer	services	in	a	given	country,	with	downstream	effects	on	facility	capabilities	(figure	14).		
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Figure	14:	Country	roadmap	to	guide	acquisition	of	capabilities	for	childhood	cancer	care	
		Context	adaptation	of	diagnostic	and	treatment	guidelines	requires	a	detailed	definition	of	the	 capabilities	 of	 the	 center	 where	 care	 is	 delivered.	 While	 the	 focus	 of	 guideline	development	 has	 emphasised	 guidance	 for	 treatment	 decisions	 based	 on	 facility	 level	resources,	 interconnectedness	 among	 facilities	 as	 a	 strategy	 to	 increase	 capabilities	 and	treatment	opportunities,	or	 to	 improve	outcomes	has	not	been	explored.	 In	the	proposed	networked-tiers	model,	while	it	is	understood	that	not	all	facilities	are	equally	equipped	to	diagnose	and	treat	all	childhood	cancers,	all	paediatric	oncology	units	must	consider	their	scope	and	role,	determine	how	they	can	improve	the	quality	of	care	and	outcomes	for	all	children	with	cancer	within	the	resource	constraints	of	their	facility,	and	how	to	establish	formal	 collaborations	 with	 other	 facilities	 in	 the	 country	 or	 region.	 Each	level	in	 the	framework	must	 provide	 the	 highest	 quality	 care	 possible	 for	 their	 scope	 and	 meet	 all	
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capabilities	defined	in	the	preceding	(lower)	levels.	Lower	level	facilities	have	unique	care	delivery	 and	 supportive	 care	 functions;	 they	 should	 not	 be	 perceived	merely	 as	 referral	centers	 to	 higher	 tier	 facilities.	Higher	 facilities	 have	 unique	 education,	 consultative,	 and	collaborative	functions;	they	are	not	merely	referral	centers	to	lower	tier	facilities	(figure	15).		Figure	15:	Desirable	capabilities	at	each	level	of	care	for	childhood	cancers	
		The	 Delphi	 study	 also	 helped	 to	 define	 the	 essential	 care	 packages	 most	 important	 for	prioritization	at	a	national	level	for	sustainable	paediatric	cancer	care,	with	integration	in	the	 country	 roadmap	 and	 facility	 tier	models.	 Defining	 care	 packages	 at	 a	 national	 level	allows	priority	setting	for	effective	care	and	investment,	promoting	enhanced	functioning	
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and	ultimately	performance	of	the	health	system	to	achieve	a	patient-level	positive	impact	that	can	be	sustained.			The	Sustainable	Pediatric	Cancer	(SuPer)	Packages	considered	four	intervention	pathways:	diagnosis,	treatment,	treatment	completion,	and	integrated.	The	SuPer	package	framework	included	three	overarching	package	sets	connected	to	the	proposed	country	roadmap	and	facility	tiers.	First,	a	Core	Sustainable	Pediatric	Cancer	(SuPer)	Package,	is	expected	to	apply	in	 most	 to	 nearly	 all	 settings,	 and	 which	 encompasses	 pediatric	 cancer	 needs	 broadly.	Second,	an	Advanced	SuPer	Package,	is	expected	to	apply	in	many	settings,	and	is	typically	introduced	 after	 the	 interventions	 in	 the	Core	Package.	 Third,	 a	Maximal	 SuPer	Package,	expected	to	currently	apply	in	a	minority	of	settings,	typically	introduced	after	interventions	outlined	in	the	Advanced	Package,	and	is	most	dependent	on	resource	and	capability	levels,	diagnoses,	and	outcomes.			This	SuPer	Package	framework	is	outlined	in	figure	16.		Given	the	overlapping	and	nuanced	contextual	differences,	 it	was	 intentional	 for	 the	boxes	not	 to	exactly	 line	up	horizontally	with	 the	 facility	 levels.	 For	 instance,	 while	 the	 Core	 SuPer	 Package	 should	 be	 feasible	including	 in	settings	with	 low	resource	capabilities	(Level	1	Childhood	Cancer	Treatment	Facilities)	 and	 starting	 in	 countries	 at	 Roadmap	 Step	 1,	 the	 Advanced	 SuPer	 Package	 is	typically	feasible	starting	only	in	settings	with	moderate	to	high	resource	capabilities		(Level	2	 to	3	Facilities)	and	 typically	 corresponding	 to	 countries	 that	are	at	Roadmap	Step	2	or	above.	The	Maximal	SuPer	Package	is	typically	considered	feasible	by	settings	with	maximal	
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resource	 capabilities	 (a	 few	 select	 Level	 3	 and	 mostly	 Level	 4	 Facilities),	 and	 typically	corresponding	to	countries	that	are	at	Roadmap	Step	3	or	above	(figure	16).		These	 three	 illustrative	 care	 packages	 offer	 an	 indicative	 framework	 for	 governments	 to	identify	and	contextualize	opportunities	for	scale-up,	aligned	to	the	tier	system	developed	for	facilities	and	the	country	roadmaps.			
Figure	 16:	 Sustainable	 Paediatric	 cancer-specific	 framework	 for	 essential	
intervention	packages	[SuPer	Packages	Framework]	
		As	 countries	have	a	heterogeneous	mix	of	 childhood	cancer	 treatment	 facility	 levels,	 it	 is	helpful	 to	 consider	 both	 facility	 levels	 and	 country	 roadmaps	 to	 contextualize	 how	 care	packages	could	be	developed.	The	Commission	noted	that	the	facility	tiers	and	the	packages	
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Figure	17:	Capabilities	needed	 to	provide	 interventions	 of	 differing	 complexity	 for	
childhood	cancers	
		Through	the	Delphi	process,	the	Commission	also	explored	how	networked	models	of	care	could	be	developed	to	facilitate	access	to	best	quality	care	possible	within	a	health	system,	as	proposed	by	other	disciplines.164,165			Since	most	 countries	 have	more	 than	 one	 paediatric	 oncology	 facility	 and	 resources	 are	always	limited.	Hence,	there	is	strong	argument	for	greater	integration	between	facilities	to	strengthen	health	systems	and	ensure	optimal	delivery	of	equitable	and	patient-centered	care.	 In	 countries	with	 only	 one	pediatric	 oncology	 care	 facility,	 improvements	 in	 health	
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		(v)	Innovative	financing:	A	further	potential	source	of	new	and	additional	funding	for	scaling	up	sustainable	care	for	childhood	cancers	is	innovative	financing	–	funding	mobilised	from	non-traditional	mechanisms.			In	2002,	the	International	Conference	on	Financing	for	Development	in	Monterrey,	Mexico,	identified	 innovative	 financing	as	a	promising	source	of	new	and	additional	 financing	 for	global	 health.199	 Since	 then,	 innovative	 financing	 mechanisms200	 (which	 link	 different	elements	of	the	financing	value	chain—namely,	resource	mobilisation,	pooling,	channelling,	resource	allocation,	and	implementation)	and	innovative	financing	instruments201	(used	to	mobilise	funding)	have	enabled	mobilisation	and	channeling	of	substantial	funds	for	health	programmes	 globally.	 Innovative	 financing	 (panel	 8)	 could	 help	 augment	 funding	 from	domestic	sources	to	catalyse	scale-up	of	services	for	childhood	cancer.			
Panel	8:	Innovative	financing	for	funding	investments	in	childhood	cancers		To	 date,	 three	 innovative	 financing	 mechanisms	 (which	 mobilise	 funding	 from	 multiple	sources,	 and	 pool,	 allocate	 and	 channel	 these	 funds	 health	 programmes	 in	 LMICs)	 have	reached	a	global	scale,	namely	the	Global	Fund	to	Fight	AIDS,	Tuberculosis	and	Malaria	(the	Global	Fund,	established	in	2002)202,	GAVI	(established	in	2000)203,	and	Unitaid	(established	in	2006).204	By	 June	2019,	 the	Global	Fund	had	disbursed	US$	41.4	billion	 for	HIV/AIDS,	tuberculosis,	malaria	and	health	systems,202	GAVI	had	disbursed	US$13.4	billion	for	vaccines	by	 November	 2018,203	 and	 by	 2017	 UNITAID	 had	 invested	 more	 than	 US$2	 billion,	 in	
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medicines,	 diagnostics	 and	 health	 products	 for	 HIV/AIDS,	 drug	 resistant	 tuberculosis,	malaria,	and	Hepatitis	C204.		Several	innovative	financing	instruments	have	been	developed	to	generate	and	mobilise	funds	totaling	around	US$8·9	billion	in	2002–15.201	For	example,	the	Airline	Solidarity	Levy,201	which	involves	a	small	tax	(levy)	on	airline	tickets	in	participating	countries,	has	generated	regular	funding	for	Unitaid.	Financial	transaction	taxes205,	introduced	to	reduce	excessive	speculation	in	financial	markets,	are	potentially	large	source	of	innovative	financing.	Countries,	such	as	South	Korea,	India,	Brazil,	Taiwan,	South	Africa	and	Switzerland	have	already	introduced	a	financial	transaction	tax	to	generate	general	tax	revenues.		Long-term	pledges	by	donors	have	been	used	as	security	to	issue	bonds	in	capital	markets.	The	International	Finance	Facility	for	Immunisation,	established	in	2006,	has	successfully	mobilised	donor	pledges	to	launch	immunization	bonds,	and	to	channel	$6	billion	in	2006-18	to	Gavi	to	accelerate	introduction	of	new	vaccines	and	expand	immunization	programmes	in	LMICs.206		Debt	conversion	has	been	used	to	convert	loans	to	grants	with	conditions	of	meeting	a	health	or	social	target.	For	example,	with	Debt2Health,	a	creditor	country	forgoes	a	portion	of	a	debt	on	 the	 condition	 that	 the	 debtor	 country	 invests	 an	 agreed	 counterpart	 amount	 by	contributing	to	the	Global	Fund	according	to	a	schedule	established	as	a	part	of	a	debt	swap	agreement	which	is	then	provided	as	a	grant	to	expand	national	health	programs	.207	
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